Skip to content
Clinical Trials – home
Verifiedinfo

Azienda Ospedaliero-Universitaria Policlinico G. Rodolico-San Marco Di Catania

Italy Via Santa Sofia 78, 95123 Catania, Italy

  • 124 trials recruiting
  • Non-small cell lung cancer · Hidradenitis · Plasma cell myeloma
  • Adults and children

About Specializations

Azienda Ospedaliero-Universitaria Policlinico G. Rodolico-San Marco Di Catania in Catania, Italy specialises in clinical trials of conditions such as Non-small cell lung cancer, Hidradenitis, Plasma cell myeloma, Idiopathic pulmonary fibrosis, and other specialisations. This site conducts important research.

Main research areas of the site

Respiratory Infections and Pulmonary Diseases

The medical center is at the forefront of research in respiratory infections and pulmonary diseases, focusing on innovative treatments and preventive measures. The center's work in this area is crucial for developing new therapies that improve patient outcomes and quality of life.

  • Recurrent Lower Respiratory Tract Infections (RLRTIs)
  • Pulmonary Sarcoidosis
  • Idiopathic Pulmonary Fibrosis (IPF)

Through rigorous clinical trials, the center is advancing the understanding of these conditions and exploring novel therapeutic approaches.

Oncology and Hematology

Specializing in oncology and hematology, the center is dedicated to pioneering research in cancer treatment, particularly in challenging cases of relapse and refractory conditions. The institution's commitment to innovation is evident in its diverse clinical trials aimed at improving survival rates and patient care.

  • Non-Small Cell Lung Cancer (NSCLC)
  • Head and Neck Squamous Cell Carcinoma (HNSCC)
  • Multiple Myeloma

The center's research is instrumental in developing targeted therapies and personalized medicine strategies.

Autoimmune and Inflammatory Diseases

With a strong focus on autoimmune and inflammatory diseases, the center is leading efforts to understand and treat complex conditions that affect millions worldwide. The research conducted here is vital for discovering new treatment modalities that can significantly alter disease progression.

  • Systemic Lupus Erythematosus (SLE)
  • Dermatomyositis
  • Hidradenitis Suppurativa (HS)

By exploring the underlying mechanisms of these diseases, the center aims to develop more effective and safer therapeutic options.

Neurology and Neurodegenerative Disorders

The center is a leader in neurology and neurodegenerative disorders, focusing on innovative research to combat these debilitating conditions. The institution's work is crucial for advancing the understanding and treatment of neurological diseases.

  • Multiple Sclerosis (MS)
  • Multiple System Atrophy (MSA)

Through cutting-edge research, the center is paving the way for new therapies that can improve patient outcomes and quality of life.

Cardiovascular and Metabolic Disorders

Focusing on cardiovascular and metabolic disorders, the center is dedicated to advancing research in these critical areas. The institution's efforts are aimed at developing new treatments that can effectively manage and prevent these widespread health issues.

  • Acute Coronary Syndrome
  • Sickle Cell Disease (SCD)

The center's research is essential for understanding the complex interactions between these disorders and developing comprehensive treatment strategies.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Via Santa Sofia 7895123 CataniaItaly
Recruiting now
124 trials
Conditions studied
160
Partner status
Verified

More sites in CataniaItaly

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

305 clinical trials

Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Azd5004
  • Sponsor:AstraZeneca AB
Countries:ItalyItaly
  • Participants:18–64 years
  • Sponsor:Zenas Biopharma (USA) LLC
Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan Hydrochloride
  • Sponsor:Zai Lab (US) LLC
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Pfizer Inc.
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB
Countries:ItalyItaly
  • Participants:18–64 years
  • Sponsor:Zenas Biopharma (USA) LLC
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Amgen Inc.
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:GSK3862995B
  • Sponsor:GSK PLC
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:IMEROPRUBART
  • Sponsor:Immunovant Sciences GmbH
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Ruxolitinib
  • Sponsor:Incyte Corp.
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:AstraZeneca AB
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).